# **Comprehensive Report on Pediatric Growth Disorders**

## **Executive Summary**

This report provides a comprehensive, evidence-based summary of key pediatric growth disorders. It meticulously details their specific impact on weight and height growth patterns, major symptoms, typical diagnosis age, diagnostic methods, available treatment options, and the expected growth trajectory following intervention. Furthermore, it outlines associated complications, emphasizing the multifaceted nature of these conditions. The central component is a detailed markdown table, rigorously compiled from credible medical sources, which is then elaborated upon through in-depth analytical sections.  
A recurring theme across various pediatric growth disorders is the profound impact of early and accurate diagnosis, coupled with timely and appropriate therapeutic interventions. Proactive management is critical for optimizing linear growth potential, mitigating irreversible neurocognitive deficits, and improving the overall long-term health and quality of life for affected children. Delays in diagnosis and treatment can lead to suboptimal adult height, persistent developmental challenges, and increased burden from comorbidities.1  
Pediatric growth disorders frequently arise from complex interactions of genetic, endocrine, and systemic factors. Effective management therefore necessitates a collaborative, multidisciplinary approach involving specialists such as pediatric endocrinologists, geneticists, gastroenterologists, nephrologists, orthopedic surgeons, neurosurgeons, dietitians, and mental health professionals. This integrated care model ensures comprehensive assessment and tailored treatment strategies to address the diverse manifestations and complications of these conditions.3

## **Introduction to Pediatric Growth Disorders**

### **Defining Normal Growth and Deviations**

Normal childhood growth is a complex, dynamic process influenced by genetic potential, adequate nutrition, and the intricate interplay of various hormones, particularly growth hormone and thyroid hormones. Understanding these physiological underpinnings is crucial for identifying deviations. Average "normal" growth rates vary significantly with age: approximately 10 inches per year during the first year of life, around 5 inches per year from 1 to 2 years, about 3.5 inches per year from 2 to 3 years, and typically 2 to 2.5 inches per year from age 3 until the onset of puberty.11 Growth disorders are characterized by significant deviations from these expected growth patterns, manifesting as either short stature (proportionate or disproportionate), excessive growth, or abnormal weight gain or loss patterns.

### **Importance of Timely Diagnosis and Comprehensive Management**

The window of opportunity for effective intervention in many growth disorders is finite, often closing with epiphyseal plate fusion. Delayed diagnosis can lead to irreversible deficits in final adult height, as well as significant cognitive, developmental, and psychosocial impairments.1 Comprehensive management extends beyond merely addressing height. It encompasses nutritional support, psychological counseling, and the treatment of associated systemic complications, emphasizing a holistic approach to patient well-being.7

### **Overview of the Multifactorial Nature of Growth Disturbances**

Pediatric growth disorders are etiologically diverse. They can stem from primary endocrine dysfunctions, such as Growth Hormone Deficiency 11 or Hypothyroidism 13; genetic syndromes like Turner Syndrome 15, Prader-Willi Syndrome 4, Achondroplasia 8, and Noonan Syndrome 16; chronic systemic illnesses including Crohn’s Disease 17, Celiac Disease 18, and Chronic Kidney Disease 19; or disorders of pubertal timing such as Precocious Puberty 12 and Delayed Puberty.20 Nutritional deficiencies can also contribute significantly to growth failure.11

### **Interconnectedness of Growth Pathways and Systemic Health**

A review of medical literature consistently demonstrates that pediatric growth disorders are rarely isolated to the growth axis. Instead, they frequently represent systemic conditions with widespread physiological implications. For instance, Crohn's disease, primarily a gastrointestinal inflammatory disorder, directly impacts growth through nutrient malabsorption and chronic inflammation.17 The chronic inflammatory state increases metabolic demand and can directly suppress growth, while damage to the intestinal lining hinders the absorption of essential nutrients required for healthy development.  
Similarly, both congenital and acquired hypothyroidism, while endocrine in nature, profoundly affect not only linear growth but also brain development, metabolism, and cardiovascular function.1 The thyroid hormones are crucial for the proper functioning of nearly every organ system, and their deficiency leads to a cascade of systemic issues beyond just stunted growth. Prader-Willi Syndrome, a genetic condition, manifests with growth abnormalities but also involves complex metabolic dysregulation, neurological deficits, and bone health issues.4 The underlying genetic defect impacts multiple pathways, leading to a constellation of symptoms including altered body composition and cognitive challenges.  
This pervasive impact across multiple organ systems suggests that growth is a highly sensitive and integrated biomarker of overall pediatric health. Growth failure, therefore, should prompt a comprehensive investigation into potential underlying systemic pathologies, rather than solely focusing on a primary growth hormone axis defect. This understanding necessitates a broad diagnostic approach that extends beyond typical growth-related hormone panels. Clinicians must consider a wide differential diagnosis and perform thorough systemic evaluations. Furthermore, effective management of growth disorders often requires addressing the primary underlying systemic disease, as direct growth interventions alone may be insufficient without controlling the root cause. This holistic perspective is crucial for optimizing long-term health outcomes.

## **Comprehensive Table of Pediatric Growth Disorders**

This comprehensive table is designed as a central, high-value component of this report. Its structured format allows medical professionals to rapidly access and compare critical information across a range of pediatric growth disorders. This facilitates efficient differential diagnosis, informs appropriate diagnostic workups, and guides evidence-based treatment planning. The inclusion of precise ICD-10 codes is essential for accurate clinical documentation, health information exchange, and epidemiological surveillance. Moreover, the "Growth Trajectory After Intervention" column provides crucial prognostic information, which is invaluable for counseling patients and their families on realistic expectations and long-term outcomes. By consolidating diverse data points into a single, organized format, the table enhances clinical utility and supports informed decision-making.

| Disorder Name | ICD-10 Code | Prevalence/Incidence | Weight Growth Pattern | Height Growth Pattern | Major Symptoms | Typical Diagnosis Age | Diagnostic Methods | Treatment Options | Growth Trajectory After Intervention | Associated Complications |
| :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- |
| Growth Hormone Deficiency | E23.0, E34.3 | 1 in 4,000 to 10,000 children | Chubby body build, truncal obesity | Noticeably short stature, slow growth, growth retardation, maturation delays | Immature appearance, prominent forehead, underdeveloped nasal bridge, fine hair, poor nail growth, high-pitched voice, delayed fontanelle closure, reduced energy, reduced muscle strength, lipid abnormalities | Often delayed, around 5 years (school entry) or 10-16 years (puberty delay) | Stimulant of GH secretion (e.g., vigorous exercise, medications) with measurement over time; rule out other disorders (genetic short stature, inadequate caloric intake, thyroid deficiency, GI problems) | Daily injections of synthetic human growth hormone (rHGH) | Many children can reach normal/near-normal adult height; results seen in 3-4 months; earlier treatment, better outcome. Mean adult height SDS from \-1.6 to \-0.7; mean change in height SDS 1.1-2.0. Benefit of 8.6-9.5 cm over untreated controls. | Decreased bone mineral density, increased cardiovascular risk factors, decreased energy level, osteoporosis, insulin resistance, impaired cardiac function |
| Turner Syndrome | Q96.0, Q96.1, Q96.2, Q96.3, Q96.4, Q96.8, Q96.9 | 1-5 per 10,000 live female births; 1 in 2,000 to 1 in 2,500 live female births | Not specifically detailed, but short stature can lead to disproportion | Short height, slowed growth, no growth spurts at expected times; untreated adult height deficit \~20 cm (3 SD reduction). Growth reduced in all phases. | Wide/weblike neck, low-set ears, broad chest with widely spaced nipples, high/narrow palate, arms turn outward at elbows, narrow/turned-up fingernails/toenails, swelling of hands/feet (at birth), cardiac defects, low hairline, receding/small lower jaw, short fingers/toes, ovarian insufficiency/failure, delayed puberty, primary amenorrhea | Peaks: \<1 year (14.9%), 10-17 years (33.2%), adulthood (38.5%). Median age \~15 years. Prenatal ultrasound findings may suggest. | Karyotype analysis (confirmatory); prenatal ultrasound | Human growth hormone (hGH) therapy (40-50 mcg/kg/d, up to 68 mcg/kg/d); estrogen replacement therapy; adjunctive oxandrolone (with caution) or delayed puberty initiation | HGH therapy often favorable response; average annual height gain of 1 cm/year; greater gains with earlier initiation (as early as 2 years). Continue until bone age 14 or height velocity \<2 cm/year. Patients can reach adult height within normal range. | Heart problems (aorta defects, hypertension), hearing loss, vision problems (strabismus, nearsightedness), kidney problems (malformations, UTI risk), autoimmune disorders (hypothyroidism, diabetes, celiac disease, IBD), skeletal problems (scoliosis, kyphosis, osteoporosis), learning disabilities, mental health issues (anxiety, depression, ADHD) |
| Prader-Willi Syndrome | Q87.1, Q87.11 | 1 in 15,000-30,000 live births worldwide | Infancy: thin due to poor feeding (hypotonia). Toddlerhood/Childhood: markedly increased appetite, rapid weight gain, obesity (consume \~3x calories of peers), decreased energy expenditure. | Short stature (due to GHD and hypogonadism), poor growth; untreated mean adult height 5'4" (boys), 4'11" (girls). Most below 5th percentile after adolescence. | Infancy: poor muscle tone, distinct facial features (almond-shaped eyes, narrow temples, turned-down mouth, thin upper lip), poor sucking reflex, poor responsiveness, underdeveloped sex organs. Childhood/Adulthood: constant food craving (hyperphagia), underdeveloped sex organs (delayed/incomplete puberty, infertility), cognitive impairment/learning disabilities, delayed motor skills, speech problems, behavioral problems (stubborn, angry, obsessive-compulsive, skin picking), sleep apnea, small hands/feet, scoliosis, high pain tolerance. | Symptoms present from birth, but diagnosis often delayed. Genetic testing can confirm. Scoring systems for 0-36 months vs. 3 years to adulthood. | Genetic testing (blood test for chromosome 15q11 deletion or maternal uniparental disomy); clinical suspicion based on symptoms. | Human growth hormone (HGH) therapy; sex hormone treatment; weight management (diet, exercise); sleep disturbance treatment; various therapies (PT, speech, OT, developmental); behavior management (schedules, food limits, medication); mental healthcare. | HGH improves height, muscle tone, motor development, reduces body fat, improves bone mineral density. Boys reached normal height (172.4 cm, \-0.87 SD), girls just below target (160 cm, \-0.90 SD) with long-term GH therapy. | Obesity, gastric perforation (after bariatric surgery), osteoporosis, sleep apnea, adrenal insufficiency, cardiovascular problems, diabetes, respiratory illnesses. |
| Achondroplasia | Q77.4 | 1 in 20,000 to 1 in 30,000 live births; global prevalence 1-9 per 100,000 | Increased risk of obesity into adulthood | Disproportionate short stature, rhizomelic shortening of extremities (short upper arms/legs), average-sized trunk, standing height below 5th percentile; adult height \~4 feet. | Large head (macrocephaly) with frontal bossing, midface hypoplasia (small nasal bridge), short fingers (brachydactyly) with trident hand, bowed legs (genu varum), limited elbow mobility, swayed lower back, foramen magnum stenosis (may cause apnea, swallowing difficulty, weakness, hypotonia), hydrocephalus, ear infections, spinal pathologies (scoliosis, kyphosis, lumbar spinal stenosis). | Often present at birth or early infancy. Prenatal diagnosis possible. | Clinical characteristics; specific radiological features (skeletal surveys); molecular genetic testing for FGFR3 mutation (confirmatory); noninvasive prenatal diagnosis (cell-free fetal DNA); sleep study and advanced imaging (CT/MRI) for sleep apnea/cervicomedullary myelopathy. | Surgical correction for hydrocephalus, foramen magnum decompression, tympanostomy tubes for hearing, bracing/surgery for kyphosis/scoliosis, nonoperative/operative for lumbar spinal stenosis, hemiepiphysiodesis/osteotomies for bowed legs. Vosoritide (recombinant C-type natriuretic peptide analog); growth hormone therapy. | Vosoritide: placebo-adjusted increase in growth velocity of 1.6 cm/year, sustained for up to 42 months. Modeling suggests Vosoritide could result in height increase of 21.7 cm (girls) and 26.4 cm (boys) compared to untreated. GH treatment alone augmented final height by \+2.8 to \+3.5 cm. | Increased mortality in early childhood (from FMS), otolaryngology problems, obesity, cervicomedullary myelopathy, hydrocephalus, hearing impairment, thoracolumbar kyphosis, lumbar spinal stenosis, bowed legs, arthritis, joint problems. |
| Congenital Hypothyroidism | E03.1 | 1 in 3,000 to 1 in 4,000 live births | Constipation, feeding difficulty | Slow growth, generalized growth retardation | Often asymptomatic at birth. Early: lethargy, hypotonia, large fontanels, feeding difficulty, prolonged jaundice, poor/hoarse cry, constipation, hypothermia. Late (after \~6 weeks): coarse facies (depressed nasal bridge, puffy eyelids, large tongue), coarse hair, thick/dry/cold mottled skin, abdominal distension, umbilical hernia, hyporeflexia, bradycardia, hypotension, anemia, noisy breathing, nasal stuffiness, intermittent perioral cyanosis. If untreated: intellectual disability. | At birth (newborn screening) | Newborn screening (NBS); thyroid function tests (low T4, high TSH for primary; low/normal TSH with low T4 for central). | Prompt initiation of levothyroxine (L-T4) replacement therapy (10-15 mcg/kg for severe cases). | If treatment begins in first two weeks, infants usually develop normally. Early and adequate therapy leads to appropriate global intelligence. Normal growth and bone age maturation. | Irreversible neurological deficits (intellectual disability) if treatment delayed; mild/subtle deficits in verbal skills, attention, memory, motor development may still occur; respiratory distress due to myxedema. |
| Precocious Puberty | E30.1, E22.8 (for central PP) | Rare, 1% or less of U.S. population. Overall incidence 1:5,000 to 1:10,000 children. Central PP affects 1 in 5,000 to 10,000 girls. Girls affected more than boys (ratio \~10:1). | Rapid growth initially; obesity is a risk factor. | Rapid growth initially, but bones mature too soon, leading to early cessation of growth and shorter adult height. | Girls: breast growth, first period. Boys: testicle/penis growth, facial hair, deeper voice. Both: pubic/underarm hair, acne, adult body odor. | Before age 8 in girls, before age 9 in boys. | Medical/family history, physical exam, blood tests (hormone levels), X-rays of hands/wrists (bone age). GnRH stimulation test to differentiate central vs. peripheral. MRI of brain for central PP, thyroid testing for hypothyroidism. | GnRH analogue therapy (monthly shots or longer intervals, histrelin implant) to delay development until usual puberty age. Treatment of underlying cause (e.g., tumor removal). | Primary goal is to reach adult height. Puberty restarts after GnRH analogue therapy stops. Average height gain of 4 cm reported, some studies show greater gains (7.9 cm with GnRHa \+ GH). Girls treated before age 6 achieve greatest final height gain. | Short adult height, social/emotional problems (distress, self-esteem issues, depression, substance use risk), early sexual activity risk. |
| Crohn’s Disease | K50.0, K50.1, K50.8, K50.9 | Incidence increasing, 2.5-11.4 per 100,000; prevalence 58 per 100,000. 20-25% of IBD patients are children \<18 years. | Reduced appetite, weight loss, malnutrition, difficulty absorbing nutrients. Growth failure in 65-85% of children. | Delayed growth, short stature, delayed development. Growth failure in 65-85% of children. Poor height and weight gain may precede other symptoms. | Diarrhea, fever, fatigue, belly pain/cramping, blood in stool, mouth sores, reduced appetite, weight loss, pain/drainage near anus (fistula), inflammation of skin/eyes/joints, inflammation of liver/bile ducts, kidney stones, anemia, delayed growth/sexual development. | Majority diagnosed in early teen years; very early onset (\<6 years) and infantile onset (\<2 years) subgroups exist. | Rule out other causes. Combination of tests: blood tests (infection, anemia, inflammation, liver function), stool studies (blood, bacteria, parasites, calprotectin), colonoscopy, CT/MR enterography, capsule endoscopy. | No cure. Goal: reduce inflammation. Anti-inflammatory medicines (corticosteroids, 5-aminosalicylates), immune system suppressors, biologics, JAK inhibitors, antibiotics, anti-diarrheals, pain relievers (acetaminophen), vitamins/supplements. Nutrition therapy (enteral/parenteral nutrition, dietary changes). Surgery for complications. | Long-term control of inflammation and adequate nutrition are essential for promoting puberty and growth. Exclusive enteral nutrition induces remission and improves nutritional status. Early introduction of immunosuppressants/biologics can achieve remission and enable catch-up growth, ideally before puberty. Infliximab therapy improved height z-score (0.5 at week 54, 1.56 at 3 years). Catch-up growth more likely in pre- or early-pubertal children. | Bowel blockage/obstruction (strictures), ulcers, fistulas, anal fissure, malnutrition (anemia, vitamin deficiencies), colon cancer risk, increased hospitalization/intestinal resection. |
| Hypothyroidism (acquired) | E03.9, E03.4, E06.3 | More common than congenital hypothyroidism. Prevalence 0.135% (1 in 740\) in pediatric population (\<22 years). Autoimmune thyroiditis (Hashimoto's) is leading cause. | Weight gain, obesity. | Growth retardation, delayed bone age, short stature. | Growth retardation, delayed psychomotor/cognitive development, excessive fatigue, weight gain, dry skin/brittle hair, bradycardia, cold intolerance, constipation. \~80% asymptomatic at diagnosis. | Frequently presents between 9-11 years, rarely before 4 years. | Blood tests: low T4/fT4, high TSH for primary hypothyroidism; TPOab and hTGab for autoimmune cause. | Levothyroxine replacement therapy. | Levothyroxine ensures normal thyroid profile and can lead to catch-up growth, but height deficit from undiagnosed period may not be fully recovered. Treated patients had lower height z-scores than controls, despite normal thyroid function. Early diagnosis is critical to mitigate long-term effects. | Growth retardation (impacting final adult height), obesity, hypercholesterolemia, elevated blood glucose/triglycerides, increased risk of diabetes, dyslipidemia, hypertension, cardiovascular disease, Slipped Capital Femoral Epiphysis (SCFE). |
| Delayed Puberty | E30.0 | Affects \~2% of adolescents. More common in males (65% of cases) than girls (30%). | Short stature, delayed growth in height and weight. Malnutrition can be a cause. | Delayed growth, short stature, delayed sexual development. Kids with constitutional delay reach appropriate adult height, just later. May be slightly smaller as adults. | Girls: lack of breast development by age 13, no menstruation by 15\. Boys: lack of testicle enlargement by age 14\. No increased growth rate. May be noticeably shorter than peers. | Girls: no breast development by 13, no menstruation by 15\. Boys: no testicle enlargement by 14\. | Medical history (prenatal, birth, developmental), physical exam (Tanner staging, growth charts, physical characteristics), laboratory tests (hormone levels: LH, FSH, thyroid, sex steroids; bone age X-ray; genetic testing). | Often no treatment needed (constitutional delay). Hormone therapy (estrogen/testosterone) to "jump start" puberty. Growth hormone if pituitary not working well. Treat underlying chronic disease (celiac, kidney, hypothyroidism) or malnutrition. | Constitutional delay: kids go through puberty and reach appropriate adult height, just later. Hormone therapy successfully "jumpstarts" puberty in most cases. May result in slightly smaller adult height compared to peers. Puberty may happen faster once started. | Short stature, osteoporosis, psychological distress, social/emotional difficulties. Fertility issues depending on cause. |
| Celiac Disease | K90.0 | 1 in 133 people in U.S. More girls affected than boys. | Weight loss or poor weight gain, decreased appetite, malnutrition. | Short stature or poor growth, stunted growth. | Classic (\<3 years): abdominal pain/cramps, distension, diarrhea, constipation, nausea, vomiting, decreased appetite, fatigue, weight loss/poor weight gain, short stature/poor growth, mouth ulcers. Atypical (older children, average diagnosis age \~9): delayed puberty, behavioral problems, iron deficiency, osteopenia/osteoporosis, hepatitis, arthritis, infertility, migraines, seizures, neuropathy. | Average diagnosis age \~9 years old (for atypical symptoms). Infants/small children not tested until age 2 unless clear signs. | Blood test (initial step, not definitive). Endoscopy with small intestine biopsies (confirmatory, crucial). Do NOT start gluten-free diet before diagnosis. Family testing recommended. | Strict lifelong gluten-free diet. Registered dietitian guidance. Medications (steroids, immunosuppressants) in rare non-responsive cases. | Damage to intestines heals, proper nutrient absorption, improved growth. Symptoms improve within days to weeks for most. | Iron deficiency anemia, low bone density (osteoporosis/osteopenia), decreased response to hepatitis B vaccine, increased risk of certain cancers and autoimmune diseases (Type 1 diabetes, hyper/hypothyroidism), irritable bowel syndrome, lactose intolerance, microscopic colitis, pancreas problems, small intestinal bacterial overgrowth, refractory celiac disease. |
| Noonan Syndrome | Q87.1, Q87.19 | 1-5 per 10,000 | Typical birth weight but slower growth over time, eating difficulties, poor nutrition/weight gain. | Short stature (50-70% affected), reduced pubertal growth spurt, adult height often below 3rd percentile. Growth reduced in all phases. | Mildly unusual facial features (deep philtrum, widely spaced/down-slanting eyes, droopy lids, low-set/rotated-back ears, high-arched palate, small lower jaw), short neck (often webbed, low hairline), chest deformities (pectus excavatum/carinatum), wide-set nipples, unusual spine curve, heart defects (pulmonary valve stenosis, hypertrophic cardiomyopathy), bleeding problems (bruising, nosebleeds), lymphedema (puffy hands/feet), delayed puberty (males), undescended testes, learning disabilities/intellectual disability, vision/hearing problems, feeding problems. | Antenatal, neonatal, infancy, childhood. | Clinical features, congenital heart defects, genetic confirmation of mutation (PTPN11, SOS1, KRAS). Prenatal diagnosis possible (increased nuchal translucency, cystic hygroma, ascites, cardiomyopathy, congenital heart defect). | Growth hormone (GH) treatment for short stature. Management of symptoms and complications. Low-dose estrogen (may improve growth). | GH treatment is beneficial, modest gains in adult height. Average increase of \~+1.4 SDS in final height observed. Early appropriate use of hGH increases adult height. | Developmental delays, bleeding/bruising issues, lymphedema, urinary tract issues, fertility issues (males), higher risk of cancer (leukemia, tumors). |
| Chronic Kidney Disease | N18.1-N18.6 | 15-74.7 cases per 1 million children. Estimated 1-3% of global pediatric population. 0.36-0.5% prevalence in children 12-17 years old in US. | Loss of appetite, weight loss, malnutrition. | Stunted/poor growth, growth failure. | Often asymptomatic until advanced stages. Foamy urine, frequent/less frequent urination, itchy/dry skin, fatigue, nausea, loss of appetite, weight loss, trouble concentrating, numbness/swelling in limbs, achy muscles/cramping, shortness of breath, vomiting, trouble sleeping, ammonia-smelling breath. Pediatric specific: prolonged bedwetting, frequent severe headaches (from high BP), anemia/pallor, bone pain, back/side/lower belly pain, irritability, poor muscle tone, change in mental alertness. | eGFR can be used for diagnosis from age 2+. Under 2 years, urine or imaging tests. | Urinalysis (proteinuria), blood tests (creatinine, cystatin, electrolytes, red blood cell count), ultrasound (kidney damage, size, shape, obstructions), kidney biopsy. GFR categories for staging. | Treat underlying cause. Manage complications (high BP, anemia, poor growth). Medications to slow worsening (reduce proteinuria). Dialysis or kidney transplant for end-stage. Growth hormone therapy (rHGH). Nutritional support, diet changes. | Growth failure is common. rHGH treatment results in significant height gain. Mean height at kidney transplant increased from \-2.4 SDS (1987) to \-1.4 SDS (2005). rHGH increased height by \~4 cm after 1 year, and further 2 cm after 2 years. Untreated patients may maintain height in normal range but may also be adversely affected. | Heart disease, stroke, anemia, bone disease, high blood pressure, fluid overload, uremia, hyperkalemia, kidney failure (ESKD), increased mortality. |

## **In-Depth Analysis of Growth Trajectories and Treatment Outcomes**

### **Physiological Basis of Growth Impairment**

The mechanisms underlying growth impairment in pediatric disorders are diverse, reflecting the complex interplay of genetic, endocrine, and environmental factors that regulate human growth.  
**Growth Hormone Deficiency (GHD)** is fundamentally characterized by an inadequate secretion of growth hormone (GH) from the anterior pituitary gland. This deficiency directly impairs the stimulation of cellular growth and proliferation, particularly in the epiphyseal plates of long bones. The consequence is proportionally short stature and delayed bone maturation, as the skeletal system does not receive the necessary signals for typical development. Children with GHD often present with a noticeably slow growth rate, an immature appearance, and a tendency towards a chubby body build or truncal obesity, despite otherwise normal body proportions.11  
**Turner Syndrome (TS)** presents with short stature that is multifactorial in origin. While individuals with TS are not classically GH-deficient, their growth is reduced across all phases of development—fetal-infancy, childhood, and puberty. A notable feature is the absence or blunting of the pubertal growth spurt. A significant contributor to this growth failure is haploinsufficiency of the SHOX gene, located on the X chromosome, which plays a critical role in skeletal development.26 Untreated, girls with TS typically experience an adult height deficit of approximately 20 cm compared to the general population.3  
In **Prader-Willi Syndrome (PWS)**, growth impairment is complex, stemming from hypothalamic dysfunction that leads to both growth hormone deficiency and hypogonadism. The lack of adequate growth hormone directly impacts linear growth, while the insufficient production of sex hormones prevents the typical pubertal growth spurt, contributing to a significantly reduced adult height. Beyond hormonal imbalances, PWS is characterized by poor muscle tone and an altered body composition, with an increased fat mass and decreased lean mass, which further distinguishes its growth pattern.4  
**Achondroplasia** represents the most common form of disproportionate short stature. This condition is caused by a specific gain-of-function mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. This mutation leads to an overactive FGFR3 receptor, which constitutively inhibits chondrocyte proliferation and differentiation in the growth plates. The result is a severe impact on the growth of long bones, leading to characteristic features such as rhizomelic shortening of the extremities (short upper arms and legs), an average-sized trunk, and an adult height typically around 4 feet.8  
Both **Congenital Hypothyroidism (CH)** and **Acquired Hypothyroidism** involve a deficiency of thyroid hormones, which are indispensable for normal skeletal growth, bone maturation, and neurological development. Inadequate thyroid hormone levels, whether present from birth or developing later, result in generalized growth retardation, delayed bone age, and, if left untreated, can lead to irreversible intellectual disability. Thyroid hormones regulate metabolism and cellular processes throughout the body, making their deficiency a systemic issue with profound effects on development.1  
**Precocious Puberty (PP)**, paradoxically, leads to reduced adult height despite an initial period of rapid growth. This occurs due to the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, resulting in early secretion of sex steroids. While these hormones initially induce an accelerated growth spurt, they also hasten epiphyseal plate fusion, leading to an early cessation of linear growth and a shorter final adult height than predicted.12  
**Crohn’s Disease (CD)** and **Celiac Disease (CeD)**, both chronic gastrointestinal disorders, cause growth failure primarily through chronic inflammation and nutrient malabsorption. Chronic inflammation increases the body's metabolic demand and can directly suppress growth pathways. In celiac disease, gluten consumption damages the villi lining the small intestine, severely impairing the absorption of essential macro- and micronutrients necessary for growth and development.9 Delayed puberty is also a common complication in these conditions.17  
**Delayed Puberty (DP)** is often a constitutional delay, representing a benign variant of normal development where the onset of puberty and subsequent growth are simply later than average for an individual's chronological age, though appropriate for their bone age.23 However, delayed puberty can also be a manifestation of underlying chronic illnesses such as celiac disease, chronic kidney disease, or hypothyroidism, or it may stem from malnutrition or specific hormonal imbalances. If these underlying conditions are not addressed, they can impact final adult height.10  
**Noonan Syndrome (NS)** is characterized by proportional short stature, which is a cardinal feature of the condition. Affected individuals often exhibit reduced growth velocity across all phases of growth, including fetal-infancy, childhood, and a blunted pubertal growth spurt. While the exact pathophysiology of short stature in NS is not fully understood, growth hormone levels may be low, and there can be a variable response to growth hormone stimulation tests.27  
**Chronic Kidney Disease (CKD)** is a significant cause of growth failure in children, with a high prevalence of this complication. The growth impairment in CKD is multifactorial, driven by malnutrition, chronic metabolic acidosis, anemia, and a state of growth hormone resistance. This resistance is largely due to elevated levels of inhibitory insulin-like growth factor-binding proteins, which reduce the bioavailability of IGF-1, a key mediator of growth hormone action. These systemic effects collectively impair the child's ability to grow normally.36

### **Efficacy and Limitations of Interventions on Growth**

Therapeutic interventions for pediatric growth disorders aim to optimize growth potential and mitigate long-term complications, though their efficacy varies depending on the underlying condition and timing of treatment.  
**Growth Hormone Therapy** is a cornerstone of treatment for several growth disorders. For **Growth Hormone Deficiency (GHD)**, daily recombinant human growth hormone (rHGH) injections are highly effective. Early detection and initiation of therapy are critical, as many children can achieve a normal or near-normal adult height. Noticeable results are often observed within three to four months, and the earlier treatment begins, the better the chance of attaining a favorable adult height.11 Studies indicate that treated children with GHD can achieve an adult height SDS ranging from \-1.6 to \-0.7, with a mean change in height SDS of 1.1-2.0, representing a benefit of 8.6-9.5 cm over untreated controls.38 However, it is important to note that not all children respond equally well to growth hormone treatment.11  
In **Turner Syndrome (TS)**, despite growth hormone deficiency not being a characteristic feature, affected individuals often respond favorably to human growth hormone (hGH) therapy. Early initiation, as early as 2 years of age, is particularly beneficial, as growth velocity declines rapidly in early childhood. An average annual height gain of 1 cm per year of therapy has been observed, with treatment typically continuing until a bone age of 14 years or when height velocity falls below 2 cm per year.3 Studies have shown that treated girls can reach an adult height within the normal range, despite some loss of prepubertal gain during puberty.26  
For **Prader-Willi Syndrome (PWS)**, human growth hormone (HGH) therapy is FDA-approved and has become standard of care. It not only aids in increasing height but also significantly improves muscle tone, motor development, and body composition by reducing body fat and increasing lean mass. It also contributes to improved bone mineral density.4 Long-term studies with GH therapy have shown that boys with PWS can reach a normal adult height (e.g., 172.4 cm, \-0.87 SD), while girls may reach just below their target height (e.g., 160 cm, \-0.90 SD).41  
In **Achondroplasia**, a newer therapeutic drug, vosoritide, a recombinant C-type natriuretic peptide analog, has shown promising results in clinical trials. This drug stimulates endochondral ossification, directly addressing the underlying mechanism of growth impairment. It has demonstrated a placebo-adjusted increase in growth velocity of 1.6 cm per year in achondroplastic children, with this effect sustained for up to 42 months.8 Modeling suggests that early and continuous vosoritide treatment could result in a substantial height increase of 21.7 cm in girls and 26.4 cm in boys compared to untreated children.42 Traditional growth hormone therapy alone has also been shown to augment final height by approximately 2.8 to 3.5 cm in these patients.43  
For **Congenital Hypothyroidism (CH)**, prompt initiation of levothyroxine (L-T4) replacement therapy is crucial. If treatment begins within the first two weeks after birth, infants typically develop normally, achieving appropriate global intelligence and normal growth and bone age maturation.1 High initial doses of L-T4 (10-15 mcg/kg) for severe cases can rapidly normalize serum TSH levels, leading to normal global IQ by four years of age and into young adulthood.1  
In cases of **Acquired Hypothyroidism**, levothyroxine replacement therapy is the primary treatment. While this therapy effectively normalizes thyroid hormone levels and can lead to catch-up growth, the height deficit incurred during the undiagnosed period may not be fully recovered.2 Studies have indicated that even with treatment, patients with acquired hypothyroidism may have a lower height z-score compared to healthy controls, underscoring the importance of early diagnosis to mitigate long-term effects on final adult height.2  
Treatment for **Precocious Puberty (PP)** primarily involves GnRH analogue therapy, which aims to delay further pubertal development until a more appropriate age. The main objective of this treatment is to allow children to achieve their full adult height, which would otherwise be compromised by premature epiphyseal fusion.5 After GnRH analogue therapy is discontinued, puberty typically resumes.5 Studies have reported an average height gain of 4 cm, with some studies showing greater gains, particularly when growth hormone is combined with GnRH analogues, resulting in a gain of approximately 7.9 cm.31 Girls who begin treatment before the age of six generally achieve the greatest final height gain.31  
For **Crohn’s Disease (CD)**, there is no cure, and treatment focuses on reducing inflammation and improving long-term prognosis. Nutritional therapy, including exclusive enteral nutrition, plays a key role in inducing disease remission and improving nutritional status, which is essential for promoting puberty and growth.6 Early introduction of immunosuppressants or biologics can achieve disease remission and enable catch-up growth, ideally before puberty.24 For example, infliximab therapy has been shown to improve height z-scores, with a median improvement of 1.56 at the end of three years in one study.32 Catch-up growth is more likely in children who are in the pre- or early-pubertal stage when treatment is initiated.32  
In **Celiac Disease (CeD)**, the only effective treatment is strict, lifelong adherence to a gluten-free diet. This allows the damaged intestinal lining to heal, restoring proper nutrient absorption and leading to improved growth.9 Symptoms often improve within days to weeks of starting the diet.47  
For **Delayed Puberty (DP)**, treatment is often not needed if it is due to constitutional delay, as children will eventually go through puberty and reach an appropriate adult height, albeit later than their peers.33 However, if the delay is causing significant psychosocial distress or is due to an underlying medical condition, hormone therapy (estrogen or testosterone) can be used to "jump start" puberty.10 While this can alleviate immediate concerns, it may result in a slightly smaller adult height compared to those who experience natural, albeit delayed, onset.33 Addressing any underlying chronic illnesses or malnutrition is also crucial for optimal growth.10  
For **Noonan Syndrome (NS)**, growth hormone (GH) treatment has been documented to result in short-term increases in growth velocity and modest gains in adult height.27 Studies have shown an average increase of approximately \+1.4 SDS in final height with GH treatment, and early appropriate use of hGH is associated with increased adult height.27  
In **Chronic Kidney Disease (CKD)**, growth failure is a common and significant complication. Recombinant human growth hormone (rHGH) therapy is used to help short children with CKD achieve a height more in keeping with their age group. Studies have shown that rHGH treatment can result in significant height gain. For instance, the mean height at kidney transplant for treated patients increased from \-2.4 SDS in 1987 to \-1.4 SDS in 2005\.36 Furthermore, rHGH has been observed to increase height by approximately 4 cm after one year of treatment and a further 2 cm after two years compared to untreated patients.37 While untreated patients may maintain their height in the normal range, they can also be adversely affected, highlighting the importance of careful monitoring and timely rHGH intervention when needed.36

## **Conclusions**

Pediatric growth disorders represent a diverse group of conditions, each with unique etiologies, clinical presentations, and impacts on a child's development. A critical observation from the comprehensive analysis is the profound interconnectedness of growth pathways with overall systemic health. Growth is not an isolated biological process but rather a sensitive indicator of a child's physiological well-being. When growth falters, it frequently signals underlying genetic, endocrine, or chronic systemic pathologies that extend far beyond simple height deficits. This understanding underscores the necessity for a broad diagnostic approach that considers the child's entire health profile, rather than narrowly focusing on growth parameters alone.  
The effectiveness of interventions across these disorders consistently highlights the paramount importance of early and accurate diagnosis. For conditions like congenital hypothyroidism, early initiation of therapy within weeks of birth is the difference between normal neurocognitive development and irreversible intellectual impairment. Similarly, in growth hormone deficiency and Turner syndrome, earlier treatment with growth hormone leads to significantly better adult height outcomes. In chronic conditions such as Crohn's disease and celiac disease, timely diagnosis and management of the primary illness are crucial for enabling catch-up growth and preventing long-term nutritional and developmental deficits.  
While treatments like growth hormone therapy or specific dietary interventions can profoundly improve growth trajectories, they often cannot fully compensate for growth lost during undiagnosed periods. This reinforces the principle that the window of opportunity for optimal intervention is finite, often closing as bone plates mature. The data also indicate that while many treatments are highly effective in improving growth, they do not always completely normalize adult height, suggesting that some degree of growth impairment may persist, or that the treatment mitigates but does not entirely reverse the underlying biological limitations.  
Therefore, a multidisciplinary approach to care is not merely beneficial but essential. Managing these complex conditions requires collaboration among a range of specialists to address the diverse manifestations and potential complications. This integrated care model, coupled with heightened awareness for early detection, stands as the most effective strategy for optimizing the health, development, and quality of life for children affected by pediatric growth disorders.

#### **Works cited**

1. Congenital Hypothyroidism \- StatPearls \- NCBI Bookshelf, accessed July 22, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK558913/](https://www.ncbi.nlm.nih.gov/books/NBK558913/)  
2. The Impact of Acquired Hypothyroidism on the Growth and ... \- MDPI, accessed July 22, 2025, [https://www.mdpi.com/2227-9067/12/3/272](https://www.mdpi.com/2227-9067/12/3/272)  
3. Turner Syndrome \- StatPearls \- NCBI Bookshelf, accessed July 22, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK554621/](https://www.ncbi.nlm.nih.gov/books/NBK554621/)  
4. Prader-Willi syndrome \- Mayo Clinic, accessed July 22, 2025, [https://www.mayoclinic.org/vid-20114213](https://www.mayoclinic.org/vid-20114213)  
5. Precocious puberty \- Diagnosis and treatment \- Mayo Clinic, accessed July 22, 2025, [https://www.mayoclinic.org/diseases-conditions/precocious-puberty/diagnosis-treatment/drc-20351817](https://www.mayoclinic.org/diseases-conditions/precocious-puberty/diagnosis-treatment/drc-20351817)  
6. Crohn's disease \- Diagnosis and treatment \- Mayo Clinic, accessed July 22, 2025, [https://www.mayoclinic.org/diseases-conditions/crohns-disease/diagnosis-treatment/drc-20353309](https://www.mayoclinic.org/diseases-conditions/crohns-disease/diagnosis-treatment/drc-20353309)  
7. Prader-Willi syndrome \- Symptoms and causes \- Mayo Clinic, accessed July 22, 2025, [https://www.mayoclinic.org/diseases-conditions/prader-willi-syndrome/symptoms-causes/syc-20355997](https://www.mayoclinic.org/diseases-conditions/prader-willi-syndrome/symptoms-causes/syc-20355997)  
8. Achondroplasia \- StatPearls \- NCBI Bookshelf, accessed July 22, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK559263/](https://www.ncbi.nlm.nih.gov/books/NBK559263/)  
9. Celiac Disease | Boston Children's Hospital, accessed July 22, 2025, [https://www.childrenshospital.org/conditions/celiac-disease](https://www.childrenshospital.org/conditions/celiac-disease)  
10. Delayed Puberty in Males & Females | Lurie Children's, accessed July 22, 2025, [https://www.luriechildrens.org/en/specialties-conditions/delayed-puberty/](https://www.luriechildrens.org/en/specialties-conditions/delayed-puberty/)  
11. Growth Hormone Deficiency | Boston Children's Hospital, accessed July 22, 2025, [https://www.childrenshospital.org/conditions/growth-hormone-deficiency](https://www.childrenshospital.org/conditions/growth-hormone-deficiency)  
12. Precocious puberty \- Symptoms and causes \- Mayo Clinic, accessed July 22, 2025, [https://www.mayoclinic.org/diseases-conditions/precocious-puberty/symptoms-causes/syc-20351811](https://www.mayoclinic.org/diseases-conditions/precocious-puberty/symptoms-causes/syc-20351811)  
13. Congenital hypothyroidism: MedlinePlus Genetics, accessed July 22, 2025, [https://medlineplus.gov/genetics/condition/congenital-hypothyroidism/](https://medlineplus.gov/genetics/condition/congenital-hypothyroidism/)  
14. ICD 10 Code for Hypothyroidism in Medical Billing \- Prospect Healthcare Solutions, accessed July 22, 2025, [https://prospecthealthcaresolutions.com/icd-10-code-for-hypothyroidism/](https://prospecthealthcaresolutions.com/icd-10-code-for-hypothyroidism/)  
15. Turner syndrome \- Symptoms & causes \- Mayo Clinic, accessed July 22, 2025, [https://www.mayoclinic.org/diseases-conditions/turner-syndrome/symptoms-causes/syc-20360782](https://www.mayoclinic.org/diseases-conditions/turner-syndrome/symptoms-causes/syc-20360782)  
16. Noonan syndrome: MedlinePlus Genetics, accessed July 22, 2025, [https://medlineplus.gov/genetics/condition/noonan-syndrome/](https://medlineplus.gov/genetics/condition/noonan-syndrome/)  
17. Crohn's disease \- Symptoms and causes \- Mayo Clinic, accessed July 22, 2025, [https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304](https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304)  
18. ICD-10 Code for Celiac disease- K90.0- Codify by AAPC, accessed July 22, 2025, [https://www.aapc.com/codes/icd-10-codes/K90.0](https://www.aapc.com/codes/icd-10-codes/K90.0)  
19. Chronic kidney disease (CKD) \- Symptoms, causes, treatment ..., accessed July 22, 2025, [https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd](https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd)  
20. ICD-10 Code for Delayed puberty- E30.0- Codify by AAPC, accessed July 22, 2025, [https://www.aapc.com/codes/icd-10-codes/E30.0](https://www.aapc.com/codes/icd-10-codes/E30.0)  
21. Dwarfism \- Symptoms and causes \- Mayo Clinic, accessed July 22, 2025, [https://www.mayoclinic.org/diseases-conditions/dwarfism/symptoms-causes/syc-20371969](https://www.mayoclinic.org/diseases-conditions/dwarfism/symptoms-causes/syc-20371969)  
22. Growth Disorders & Short Stature \- Riley Children's Health, accessed July 22, 2025, [https://www.rileychildrens.org/health-info/growth-disorders-short-stature](https://www.rileychildrens.org/health-info/growth-disorders-short-stature)  
23. Delayed puberty \- Wikipedia, accessed July 22, 2025, [https://en.wikipedia.org/wiki/Delayed\_puberty](https://en.wikipedia.org/wiki/Delayed_puberty)  
24. Crohn's disease and growth deficiency in children and adolescents \- PMC \- PubMed Central, accessed July 22, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4188880/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4188880/)  
25. Growth Hormone Deficiency \- Symptoms, Causes, Treatment | NORD, accessed July 22, 2025, [https://rarediseases.org/rare-diseases/growth-hormone-deficiency/](https://rarediseases.org/rare-diseases/growth-hormone-deficiency/)  
26. Normalization of puberty and adult height in girls with Turner syndrome: results of the Swedish Growth Hormone trials initiating transition into adulthood \- Frontiers, accessed July 22, 2025, [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1197897/full](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1197897/full)  
27. Short stature and its treatment in Turner and Noonan syndromes \- ern ithaca, accessed July 22, 2025, [https://ern-ithaca.eu/wp-content/uploads/2020/12/Chacko\_Noonan\_growth\_CurrOpinEndocrinDiabObes2012.pdf](https://ern-ithaca.eu/wp-content/uploads/2020/12/Chacko_Noonan_growth_CurrOpinEndocrinDiabObes2012.pdf)  
28. Growth Hormone \- Prader-Willi Syndrome Association, accessed July 22, 2025, [https://www.pwsausa.org/wp-content/uploads/2024/01/Growth-Hormone-booklet-third-Edition\_FINAL.pdf](https://www.pwsausa.org/wp-content/uploads/2024/01/Growth-Hormone-booklet-third-Edition_FINAL.pdf)  
29. Real-World Safety and Effectiveness of Vosoritide in Children with Achondroplasia: French Early Access Program \- Karger Publishers, accessed July 22, 2025, [https://karger.com/hrp/article/doi/10.1159/000543743/919732/Real-World-Safety-and-Effectiveness-of-Vosoritide](https://karger.com/hrp/article/doi/10.1159/000543743/919732/Real-World-Safety-and-Effectiveness-of-Vosoritide)  
30. Precocious puberty \- Wikipedia, accessed July 22, 2025, [https://en.wikipedia.org/wiki/Precocious\_puberty](https://en.wikipedia.org/wiki/Precocious_puberty)  
31. Final Adult Height in Girls Treated with GnRH Analogues for Precocious Puberty Around Age Eight \- PubMed Central, accessed July 22, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12191864/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12191864/)  
32. The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn's Disease \- Gut and Liver, accessed July 22, 2025, [https://www.gutnliver.org/journal/view.html?pn=vol\&uid=1302\&vmd=Full](https://www.gutnliver.org/journal/view.html?pn=vol&uid=1302&vmd=Full)  
33. Delayed Puberty/Delayed Sexual Development | Boston Children's Hospital, accessed July 22, 2025, [https://www.childrenshospital.org/conditions/delayed-puberty-delayed-sexual-development](https://www.childrenshospital.org/conditions/delayed-puberty-delayed-sexual-development)  
34. Noonan syndrome \- Symptoms and causes \- Mayo Clinic, accessed July 22, 2025, [https://www.mayoclinic.org/diseases-conditions/noonan-syndrome/symptoms-causes/syc-20354422](https://www.mayoclinic.org/diseases-conditions/noonan-syndrome/symptoms-causes/syc-20354422)  
35. Evaluation of Growth Characteristics and Final Height of Cases Diagnosed with Noonan Syndrome on Growth Hormone Treatment, accessed July 22, 2025, [https://jcrpe.org/articles/evaluation-of-growth-characteristics-and-final-height-of-cases-diagnosed-with-noonan-syndrome-on-growth-hormone-treatment/jcrpe.galenos.2024.2024-7-3](https://jcrpe.org/articles/evaluation-of-growth-characteristics-and-final-height-of-cases-diagnosed-with-noonan-syndrome-on-growth-hormone-treatment/jcrpe.galenos.2024.2024-7-3)  
36. Growth and Recombinant Human Growth Hormone Use in Children with Congenital Chronic Kidney Disease: A Multicentric Contemporary Study \- Karger Publishers, accessed July 22, 2025, [https://karger.com/hrp/article/doi/10.1159/000543435/919195/Growth-and-rhGH-use-in-children-with-congenital](https://karger.com/hrp/article/doi/10.1159/000543435/919195/Growth-and-rhGH-use-in-children-with-congenital)  
37. Growth hormone for children with chronic kidney disease \- PMC \- PubMed Central, accessed July 22, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6599873/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599873/)  
38. Prediction of Adult Height in Growth-Hormone-Treated Children with ..., accessed July 22, 2025, [https://academic.oup.com/jcem/article/92/3/925/2597341](https://academic.oup.com/jcem/article/92/3/925/2597341)  
39. Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit \- PubMed Central, accessed July 22, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4114101/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4114101/)  
40. Growth Hormone Therapy for PWS \- Foundation for Prader-Willi Research, accessed July 22, 2025, [https://www.fpwr.org/blog/growth-hormone-therapy-for-pws](https://www.fpwr.org/blog/growth-hormone-therapy-for-pws)  
41. A contemporary treatment regimen normalizes muscle mass and adult height in children with Prader-Willi syndrome \- a longitudinal analysis \- OAE Publishing Inc., accessed July 22, 2025, [https://www.oaepublish.com/articles/rdodj.2025.07](https://www.oaepublish.com/articles/rdodj.2025.07)  
42. BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings, accessed July 22, 2025, [https://investors.biomarin.com/news/news-details/2025/BioMarin-Presents-New-Data-for-VOXZOGO-vosoritide-in-Children-with-Achondroplasia-and-Other-Skeletal-Conditions-at-Two-International-Endocrinology-Meetings/default.aspx](https://investors.biomarin.com/news/news-details/2025/BioMarin-Presents-New-Data-for-VOXZOGO-vosoritide-in-Children-with-Achondroplasia-and-Other-Skeletal-Conditions-at-Two-International-Endocrinology-Meetings/default.aspx)  
43. Final adult height in long-term growth hormone-treated achondroplasia patients, accessed July 22, 2025, [https://www.researchgate.net/publication/316957994\_Final\_adult\_height\_in\_long-term\_growth\_hormone-treated\_achondroplasia\_patients](https://www.researchgate.net/publication/316957994_Final_adult_height_in_long-term_growth_hormone-treated_achondroplasia_patients)  
44. The Impact of Acquired Hypothyroidism on the Growth and Metabolic Profiles of Pediatric Patients: A Retrospective Monocentric Study \- PubMed Central, accessed July 22, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11941351/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11941351/)  
45. Precocious Puberty \- Early Puberty: Symptoms & Causes, accessed July 22, 2025, [https://my.clevelandclinic.org/health/diseases/21064-precocious-early-puberty](https://my.clevelandclinic.org/health/diseases/21064-precocious-early-puberty)  
46. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone \- PubMed, accessed July 22, 2025, [https://pubmed.ncbi.nlm.nih.gov/10022399/](https://pubmed.ncbi.nlm.nih.gov/10022399/)  
47. Definition & Facts for Celiac Disease \- NIDDK, accessed July 22, 2025, [https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/definition-facts](https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/definition-facts)